Royalty Report: Medical, Diagnostic – Collection: 6697


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6697

License Grant
The Licensor and the French Licensee desire to establish a product co-development relationship in order to improve technology development efficiency, with a goal of modifying the Licensor's Assays so that the Licensee and its Affiliates can commercialize them as part of a system that includes standard or modified versions of their chemistry analyzers, serology instruments or other instruments. Each Party will be liable for its own costs, expenses and liabilities incurred under this Agreement.
License Property
During the period that is the earlier of five years after the effective date, or three years after the Sale of the first Product, the Licensor will not directly or indirectly develop or commercialize any product that would compete with the Systems, except to the extent that such products are commercially available or in development prior to the effective date.

System means a combination of a New Corgenix Assay and an Elitech Analyzer.

Licensor has developed and is commercializing immunoassays for specific tests related to human health

Licensee have product lines that include chemistry analyzers and reagents and the capability to modify those products and to design and manufacture other in vitro diagnostic products.

Field of Use
The Licensee desires to obtain a Joint Product Development Agreement to modify the Licensor's Assays to be used as part of a system that includes their chemistry analyzers, serology instruments or other instruments.

IPSCIO Record ID: 4253

License Grant
The Licensee entered into a First Amended Joint Product Development Agreement with the French Licensor and Affiliate.
License Property
The Parties entered into a Joint Product Development Agreement on July 16, 2010, for the purpose of establishing a product co-development relationship with respect to Licensee immunoassays.

The Licensor is a worldwide manufacturer and distributor of Invitro Diagnostic Equipment, chemical analyzers and reagents.

This Agreement replaces the 2010 Agreement, whereby existing Licensee Assays may be modified and new Assays developed and commercialized by the Licensor and its affiliates.

Field of Use
The Licensee will pay the Licensor a royalty on net product sales of new IT Assays sold by the Licensee.

IPSCIO Record ID: 300607

License Grant
The Company has the rights to use certain raw materials in the manufacture of Vitamin D diagnostic tests.
License Property
Vitamin D diagnostic tests are for reagents that are used in its FastPack Vitamin D Assay.

The FastPack System is for the treatment of cancer and infectious diseases using nanoparticle coating technology similar to the core nanoparticle coating technology.

The FastPack System is a proprietary diagnostics platform launched in 2001. This novel, rapid and highly accurate immunoassay testing system consists of the FastPack Analyzer and the FastPack test pouch; a single-use, disposable, foil packet which includes the FastPack reagent chemistry. Since the initial conception of the system, the Company has developed two versions of its analyzer and test pouch (1.0 and IP) and has expanded its assay menu to 10, including tests for prostate cancer, thyroid function, metabolic disorders and research applications.

Field of Use
FastPack® IP Vitamin D Immunoassay
Vitamin D, known as the sunshine vitamin, is part of a group of fat-soluble prohormones which encourage the metabolism of calcium and phosphorus in the body. Increasing research is now uncovering evidence illustrating the importance of vitamin D in the protection against a whole host of health issues. It is also estimated that as much as half the population in the world is deficient in vitamin D. The FastPack® IP Vitamin D immunoassay is intended for the quantitative determination of total 25-hydroxyvitamin D and other hydroxylated metabolites in human serum and plasma. This assay is designed for use with the FastPack® IP System which is designed specifically for use in the practice laboratory setting.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.